Stoke Therapeutics Reports Q2 2026 Financial Results

What Happened
Stoke Therapeutics, Inc. announced and filed an 8‑K (Item 2.02) on August 3, 2026 to disclose its financial results for the quarter ended June 30, 2026. The company issued a press release reporting those quarterly results (filed as Exhibit 99.1).

Key Details

• Press release announcing quarter results dated August 3, 2026 (Exhibit 99.1).
• Reporting period: quarter ended June 30, 2026.
• Form 8‑K filed under Item 2.02 (Results of Operations and Financial Condition).
• Report signed by Thomas E. Leggett, Chief Financial Officer, on behalf of the company.

Why It Matters
This filing signals Stoke has publicly released its quarterly earnings and financial condition information; investors should review the attached press release (Exhibit 99.1) for revenue, net income/loss, cash position, and any guidance or operational updates. The 8‑K is a timely disclosure — follow-up filings (e.g., the quarterly report on Form 10‑Q) may provide more detailed financial statements and management discussion.